A015540 Stock Overview
THELMA Therapeutics Co., Ltd. operates as a biopharmaceutical company in South Korea and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
THELMA Therapeutics Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩70.00 |
| 52 Week High | ₩300.00 |
| 52 Week Low | ₩55.00 |
| Beta | 0.26 |
| 1 Month Change | -98.91% |
| 3 Month Change | -98.91% |
| 1 Year Change | n/a |
| 3 Year Change | -98.99% |
| 5 Year Change | -99.05% |
| Change since IPO | -100.00% |
Recent News & Updates
Recent updates
Shareholder Returns
| A015540 | KR Media | KR Market | |
|---|---|---|---|
| 7D | -6.7% | 2.3% | 0.8% |
| 1Y | n/a | -10.5% | 6.3% |
Return vs Industry: Insufficient data to determine how A015540 performed against the KR Media industry.
Return vs Market: Insufficient data to determine how A015540 performed against the KR Market.
Price Volatility
| A015540 volatility | |
|---|---|
| A015540 Average Weekly Movement | 35.9% |
| Media Industry Average Movement | 4.5% |
| Market Average Movement | 5.1% |
| 10% most volatile stocks in KR Market | 11.7% |
| 10% least volatile stocks in KR Market | 2.3% |
Stable Share Price: A015540's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine A015540's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1981 | 4 | Lee Kyu | thelma.co.kr |
THELMA Therapeutics Co., Ltd. operates as a biopharmaceutical company in South Korea and internationally. The company develops TLM-01, a non-alcoholic steatohepatitis drug; TLM-02, an antiviral agent for COVID-19; TLM-03/TLM-04, an anticancer drug for solid and blood cancer; and TLM-05, a liver cancer drug. It also offers radioembolization and brachytherapy devices for the cancer treatments.
THELMA Therapeutics Co., Ltd. Fundamentals Summary
| A015540 fundamental statistics | |
|---|---|
| Market cap | ₩4.37b |
| Earnings (TTM) | -₩3.36b |
| Revenue (TTM) | ₩6.51b |
0.7x
P/S Ratio-1.3x
P/E RatioIs A015540 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A015540 income statement (TTM) | |
|---|---|
| Revenue | ₩6.51b |
| Cost of Revenue | ₩6.45b |
| Gross Profit | ₩52.97m |
| Other Expenses | ₩3.42b |
| Earnings | -₩3.36b |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -53.91 |
| Gross Margin | 0.81% |
| Net Profit Margin | -51.67% |
| Debt/Equity Ratio | 10.7% |
How did A015540 perform over the long term?
See historical performance and comparison